TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm dedicated to developing advanced therapeutic platforms that tackle the root causes of diseases, rather than just managing symptoms. Its flagship drug platform, MYMD-1, is a small molecule currently undergoing clinical trials. This platform functions by modulating the immune system to regulate TNF-alpha—a key driver of chronic inflammation—and other pro-inflammatory cytokines.